Efficacy And Safety Of Nintedanib In Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis Of The Senscis Trial By Corticosteroid Use

Background/purpose: Nintedanib reduced the rate of decline in FVC over 52 weeks compared with placebo (− 52.4 versus − 93.3 mL/year; difference 41.0 mL/year [95% CI 2.9, 79.0]; p = 0.04) in the SENSCIS trial in SSC-ILD, with manageable adverse events (AEs). Corticosteroids (CS) are commonly used in SSc-ILD, despite a lack of evidence of efficacy. We assessed the efficacy and safety of nintedanib in patients who did/did not use CS in the SENSCIS trial.